Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deferred Tax Liability: 2019-2020

  • Silence Therapeutics' Non-Current Deferred Tax Liability rose 6.98% to $33,011 in Q4 2020 from the same period last year, while for Dec 2020 it was $33,011, marking a year-over-year increase of 6.98%. This contributed to the annual value of $32,104 for FY2020, which is 4.76% up from last year.
  • Latest data reveals that Silence Therapeutics reported Non-Current Deferred Tax Liability of $33,011 as of Q4 2020, which was up 6.98% from $30,857 recorded in Q4 2019.
  • In the past 5 years, Silence Therapeutics' Non-Current Deferred Tax Liability registered a high of $33,011 during Q4 2020, and its lowest value of $30,857 during Q4 2019.
  • Over the past 2 years, Silence Therapeutics' median Non-Current Deferred Tax Liability value was $31,934 (recorded in 2019), while the average stood at $31,934.
  • Data for Silence Therapeutics' Non-Current Deferred Tax Liability shows a peak YoY rose of 6.98% (in 2020) over the last 5 years.
  • Over the past 2 years, Silence Therapeutics' Non-Current Deferred Tax Liability (Quarterly) stood at $30,857 in 2019, then rose by 6.98% to $33,011 in 2020.